Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 6, Issue 5, 2025

Moses Holmium Laser in Prostate Enucleation: Application and Future Prospects – A Review

Download as PDF

DOI: 10.23977/medsc.2025.060520 | Downloads: 1 | Views: 38

Author(s)

Kai Li 1, Weidong Yang 1, Dongqing Wang 1

Affiliation(s)

1 Department of Urology, Affiliated Hospital of Hebei University, Baoding, Hebei, China

Corresponding Author

Kai Li

ABSTRACT

Moses Holmium Laser technology has emerged as a significant advancement in the surgical treatment of benign prostatic hyperplasia (BPH), particularly in prostate enucleation procedures. This review provides a comprehensive overview of the fundamental principles underlying holmium laser technology and highlights the innovative features introduced by the Moses technique. Current clinical applications of the Moses Holmium Laser demonstrate notable advantages including enhanced surgical efficiency, superior hemostasis, and improved postoperative recovery outcomes compared to conventional methods. The article critically examines recent clinical studies and technological enhancements that have refined the application of this laser system in urological surgery. Furthermore, it explores the evolving role and potential future developments of Moses Holmium Laser within the broader scope of urology, emphasizing its capacity to optimize patient care and surgical precision. By synthesizing existing evidence and emerging trends, this review aims to offer clinicians and researchers a systematic reference framework to facilitate the continued advancement and widespread adoption of Moses Holmium Laser technology in prostate enucleation.

KEYWORDS

Moses Holmium Laser, Prostate Enucleation, Benign Prostatic Hyperplasia, Laser Surgery, Urology

CITE THIS PAPER

Kai Li, Weidong Yang, Dongqing Wang, Moses Holmium Laser in Prostate Enucleation: Application and Future Prospects – A Review. MEDS Clinical Medicine (2025) Vol. 6: 140-148. DOI: http://dx.doi.org/10.23977/medsc.2025.060520.

REFERENCES

[1] Montiel-Jarquín ÁJ, Gutiérrez-Quiroz CT, Pérez-Vázquez AL, Ortiz-Agustín JJ, García-Galicia A, Loría-Castellanos J. Quality of life and erectile dysfunction in patients with benign prostatic hyperplasia. Cir Cir. 2021;89(2):218-222. doi:10.24875/CIRU.20000071 https://pubmed.ncbi.nlm.nih.gov/33784271/
[2] Park S, Ryu JM, Lee M. Quality of Life in Older Adults with Benign Prostatic Hyperplasia. Healthcare (Basel). 2020;8(2). Published 2020 Jun 4. doi:10.3390/healthcare8020158 https://pubmed.ncbi.nlm.nih.gov/32512888/
[3] Park S, Lee KS, Choi M, Lee M. Factors associated with quality of life in patients with benign prostatic hyperplasia, 2009-2016. Medicine (Baltimore). 2022;101(36):e30091. doi:10.1097/MD.0000000000030091 https://pubmed.ncbi.nlm.nih.gov/36086750/
[4] Lee SU, Lee SH, So AH, et al. Association between benign prostatic hyperplasia and suicide in South Korea: A nationwide retrospective cohort study. PLoS One. 2022;17(3):e0265060. Published 2022 None. doi:10.1371/journal.pone.0265060 https://pubmed.ncbi.nlm.nih.gov/35271681/
[5] Inamura S, Terada N. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options. Int J Urol. 2024;31(9):968-974. doi:10.1111/iju.15518 https://pubmed.ncbi.nlm.nih.gov/38934050/
[6] Tsunemori H, Sugimoto M. Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review. Int J Urol. 2021;28(11):1086-1092. doi:10.1111/iju.14644 https://pubmed.ncbi.nlm.nih.gov/34342061/
[7] Waleed A, Hussain M, Daniyal M, Abbas SZ, Gazder T, Naz K. Assessing quality of life before and after transurethral resection of the prostate in benign prostatic hyperplasia patients. J Pak Med Assoc. 2025;75(6):935-939. doi:10.47391/JPMA.21189 https://pubmed.ncbi.nlm.nih.gov/40698471/
[8] Gong C, Zou S, Cui S. The Impact of Plasmakinetic Resection and Conventional Transurethral Resection of the Prostate on Clinical Symptoms and Quality of Life in Patients with Benign Prostatic Hyperplasia: Retrospective Cohort Study. Urol J. 2025;22(2):106-113. Published 2025 Mar 2. doi:10.22037/uj.v22i.8330 https://pubmed.ncbi.nlm.nih.gov/40057831/
[9] Rijo E, Hindley R, Tabatabaei S, Bach T. Minimally invasive surgery for benign prostatic obstruction: new insights and future technical standards. Curr Opin Urol. 2021;31(5):461-467. doi:10.1097/MOU.0000000000000918 https://pubmed.ncbi.nlm.nih.gov/34231545/
[10] Baboudjian M, Pradere B. [Office-based therapies for benign prostatic hyperplasia : Update on new minimally invasive surgery therapies]. Prog Urol. 2021;31(14):931-936. doi:10.1016/j.purol.2021.08.039 https://pubmed.ncbi.nlm.nih.gov/34456141/
[11] Chughtai B, Rojanasarot S, Neeser K, et al. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. PLoS One. 2022;17(4):e0266824. Published 2022 None. doi:10.1371/journal.pone.0266824 https://pubmed.ncbi.nlm.nih.gov/35427376/
[12] Wang K, Chen M, Liu Y, Xiao W, Qian Y, Liu X. Efficacy and Safety of Prostatic Artery Embolization in the Treatment of High Risk Benign Prostatic Hyperplasia and its Influence on Postoperative Life Quality of Patients. Front Surg. 9:905394. Published 2022 None. doi:10.3389/fsurg.2022.905394 https://pubmed.ncbi.nlm.nih.gov/35656089/
[13] Salem J, Becher KF, Bschleipfer T, et al. [Minimally invasive treatment of benign prostatic hyperplasia : The German S2e guideline 2023-part 4]. Urologie. 2024;63(1):58-66. doi:10.1007/s00120-023-02249-4 https://pubmed.ncbi.nlm.nih.gov/38193989/
[14] Schumacher S, Marghawal D, Brunken C, Herzberg J. Patient reported outcome and quality of life measured by a simple questionnaire in patients with symptomatic benign prostate hyperplasia treated by holmium laser enucleation of the prostate (HoLEP). Front Surg. 11:1358701. Published 2024 None. doi:10.3389/fsurg.2024.1358701 https://pubmed.ncbi.nlm.nih.gov/38389860/
[15] Gazel E, Kaya E, Yalcın S, et al. The low power effect on holmium laser enucleation of prostate (HoLEP); A comparison between 20W and 37,5W energy regarding apical enucleation efficacy and patient safety. Prog Urol. 2020;30(12):632-638. doi:10.1016/j.purol.2020.05.009 https://pubmed.ncbi.nlm.nih.gov/32814658/
[16] Ashraf Y, Ali S, Zamzami M, Abedin A. Next-Generation Moses Pulse Modulation: An Evaluation of Whether This Is Hype or Breakthrough. Cureus. 2025;17(8):e89298. Published 2025 Aug. doi:10.7759/cureus.89298 https://pubmed.ncbi.nlm.nih.gov/40909047/
[17] Piñero A, Narváez A, Placer J, Miret E, Trilla E, Morote J. A review of the Moses effect and its applications in endourology. Curr Urol. 2024;18(4):257-264. doi:10.1097/CU9.0000000000000239 https://pubmed.ncbi.nlm.nih.gov/40256292/
[18] Corsini C, de Angelis M, Villa L, et al. Holmium: yttrium-aluminum-garnet laser with Moses: does it make a difference? Curr Opin Urol. 2022;32(3):324-329. doi:10.1097/MOU.0000000000000979 https://pubmed.ncbi.nlm.nih.gov/35266913/
[19] Black KM, Aldoukhi AH, Teichman JMH, et al. Pulse modulation with Moses technology improves popcorn laser lithotripsy. World J Urol. 2021;39(6):1699-1705. doi:10.1007/s00345-020-03282-0 https://pubmed.ncbi.nlm.nih.gov/32506386/
[20] Elmansy H, Boudreau R, Hodhod A, et al. Second-generation MOSES 2.0 versus MOSES 1.0 pulse-modulation technologies for holmium laser enucleation of the prostate (HoLEP). World J Urol. 2024;42(1):577. Published 2024 Oct 16. doi:10.1007/s00345-024-05277-7 https://pubmed.ncbi.nlm.nih.gov/39412530/
[21] Nevo A, Faraj KS, Cheney SM, et al. Holmium laser enucleation of the prostate using Moses 2.0 vs non-Moses: a randomised controlled trial. BJU Int. 2021;127(5):553-559. doi:10.1111/bju.15265 https://pubmed.ncbi.nlm.nih.gov/33025749/
[22] Kavoussi NL, Nimmagadda N, Robles J, et al. MOSESTM Technology for Holmium Laser Enucleation of the Prostate: A Prospective Double-Blind Randomized Controlled Trial. J Urol. 2021;206(1):104-108. doi:10.1097/JU.0000000000001693 https://pubmed.ncbi.nlm.nih.gov/33617333/
[23] Assmus MA, Lee MS, Sivaguru M, et al. Laser fiber degradation following holmium laser enucleation of the prostate utilizing Moses technology versus regular mode. World J Urol. 2022;40(5):1203-1209. doi:10.1007/s00345-022-03951-2 https://pubmed.ncbi.nlm.nih.gov/35166893/
[24] Sun F, Yao H, Bao X, et al. The Efficacy and Safety of HoLEP for Benign Prostatic Hyperplasia With Large Volume: A Systematic Review and Meta-Analysis. Am J Mens Health. 2022 Jul-Aug;16(4):15579883221113203. doi:10.1177/15579883221113203 https://pubmed.ncbi.nlm.nih.gov/35864746/
[25] Large T, Nottingham C, Stoughton C, Williams J Jr, Krambeck A. Comparative Study of Holmium Laser Enucleation of the Prostate With MOSES Enabled Pulsed Laser Modulation. Urology. 136:196-201. doi:10.1016/j.urology.2019.11.029 https://pubmed.ncbi.nlm.nih.gov/31790785/
[26] Wu D, Yi XM, Wei HX, et al. [Application of 1470 nm semiconductor laser in the treatment of benign prostatic hyperplasia in ultra-aged patients]. Zhonghua Nan Ke Xue. 2023;29(9):831-836. https://pubmed.ncbi.nlm.nih.gov/38639597/
[27] Sancı A, Özkaya MF, Oguz ES, et al. Perioperative adverse events and functional outcomes following open and robot-assisted prostatectomy in patients over age 70. Int J Clin Pract. 2021;75(11):e14754. doi:10.1111/ijcp.14754 https://pubmed.ncbi.nlm.nih.gov/34431181/
[28] Yao W, Wu F, Zhang D, et al. Impacts of preoperative maximum detrusor pressure on minimally invasive surgery effect on patients with benign prostatic hyperplasia. Minerva Chir. 2020;75(1):25-29. doi:10.23736/S0026-4733.18.07880-X https://pubmed.ncbi.nlm.nih.gov/30600962/
[29] Nottingham CU, Large T, Agarwal DK, Rivera ME, Krambeck AE. Comparison of Newly Optimized Moses Technology vs Standard Holmium:YAG for Endoscopic Laser Enucleation of the Prostate. J Endourol. 2021;35(9):1393-1399. doi:10.1089/end.2020.0996 https://pubmed.ncbi.nlm.nih.gov/33813861/
[30] Gauhar V, Gilling P, Pirola GM, et al. Does MOSES Technology Enhance the Efficiency and Outcomes of Standard Holmium Laser Enucleation of the Prostate? Results of a Systematic Review and Meta-analysis of Comparative Studies. Eur Urol Focus. 2022;8(5):1362-1369. doi:10.1016/j.euf.2022.01.013 https://pubmed.ncbi.nlm.nih.gov/35105516/
[31] Klett DE, Baird B, Ball CT, Dora CD. Does MOSES pulse modulation reduce short-term catheter reinsertion following holmium laser enucleation of the prostate? Investig Clin Urol. 2021;62(6):666-671. doi:10.4111/icu.20210182 https://pubmed.ncbi.nlm.nih.gov/34729966/
[32] Hartung FO, Egen L, Gruene B, et al. Pulse modulation in En-Bloc HoLEP: does it really matter? A propensity score matched analysis. World J Urol. 2024;42(1):154. Published 2024 Mar 14. doi:10.1007/s00345-024-04830-8 https://pubmed.ncbi.nlm.nih.gov/38483598/
[33] Li K, Meng C, Li J, et al. Efficiency and clinical outcomes of Moses technology for holmium laser enucleation of the prostate: An evidence-based analysis. Prostate. 2023;83(1):3-15. doi:10.1002/pros.24438 https://pubmed.ncbi.nlm.nih.gov/36131555/
[34] Enikeev D, Shariat SF, Taratkin M, Glybochko P. The changing role of lasers in urologic surgery. Curr Opin Urol. 2020;30(1):24-29. doi:10.1097/MOU.0000000000000695 https://pubmed.ncbi.nlm.nih.gov/31724998/
[35] Morozov A, Skossyrskiy V, Babaevskaya D, Gauhar V, Enikeev D. Differences in lasers and laser technologies: what does a clinician need to know? Curr Opin Urol. 2025;35(4):354-359. doi:10.1097/MOU.0000000000001264 https://pubmed.ncbi.nlm.nih.gov/39834156/
[36] DeRoma KR, Lanzafame R, Adey G, Lerner LB. Illuminating Gaps in Laser Education in Urology Residency Programs. J Endourol. 2025;39(10):1068-1077. doi:10.1177/08927790251360267 https://pubmed.ncbi.nlm.nih.gov/40711970/ 

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 10098
Visits: 692848

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.